Factor Therapeutics expects to report top-line results before the end of the year from its randomised Phase IIb trial of VF-001 in venous leg ulcer (VLU) patients. The trial has been designed to recruit patients with VLU with moderate severity, the subgroup that responded best to VF-001 in a previous Phase II trial. Positive results would enable submission for CE mark approval in Europe and clear the way to pivotal Phase III studies in the US. We roll our risked NPV model forward following re
23 Feb 2017
Key venous leg ulcer Phase IIb underway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Key venous leg ulcer Phase IIb underway
Dominion Minerals Limited (DLM:ASX) | 0 0 0.0%
- Published:
23 Feb 2017 -
Author:
Dr Dennis Hulme -
Pages:
7
Factor Therapeutics expects to report top-line results before the end of the year from its randomised Phase IIb trial of VF-001 in venous leg ulcer (VLU) patients. The trial has been designed to recruit patients with VLU with moderate severity, the subgroup that responded best to VF-001 in a previous Phase II trial. Positive results would enable submission for CE mark approval in Europe and clear the way to pivotal Phase III studies in the US. We roll our risked NPV model forward following re